Burma (Myanmar) Healthcare

Burma importers in the healthcare business faced quick policy revisions in 2021-2022, including additional import licensing requirements, an uncertain exchange rate environment, and the prohibition of foreign currency outbound transactions.

While the Burmese economy has suffered setbacks, some sectors have gradually stabilized over the last six months. Compared to other industries, the healthcare industry received some regulatory relief since it serves as a cornerstone and an essential commercial pillar for the country. 

Healthcare product importers have been attempting to provide quality care to the Burmese people. Advanced private hospitals have begun to digitalize hospital management, upgrade treatment regimes, and offer telemedicine in preparation for an economic rebound. Given overall needs throughout the healthcare sector, Burma offers significant export opportunities for U.S. firms, especially in medical services, technical expertise, high technology diagnostic activities in hospitals and clinics, healthcare infrastructure and hospital digitalization transformation, and the establishment of private medical institutes and training facilities.

Since July-August 2022, import license restrictions have been relaxed for healthcare-related products. Importers still must find a mechanism for payments to manufacturers and international suppliers since outbound foreign currency transactions are restricted.

Before doing business in Burma, visit www.trade.gov/burma for the latest updates on sanctions, export controls and the investment climate for Burma.

For assistance with Burma Consumer Goods Sector, U.S. exporters can contact the U.S. Commercial Service Department at office.burma@trade.gov